New Cystic Fibrosis Triple-Drug Therapy Reduces Treatment Burden

A new multi-site study shows that people with cystic fibrosis who start the triple-drug therapy elexacaftor, tezacaftor, and ivacaftor can safely reduce many of their daily lung treatments while maintaining good health for years.

This breakthrough represents a significant advancement in the management of cystic fibrosis, potentially improving the quality of life for many patients. The research indicates that the therapy can lessen the treatment burden without compromising health outcomes.